Literature DB >> 19228972

Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.

Rona K Graham1, Mahmoud A Pouladi, Prasad Joshi, Ge Lu, Yu Deng, Nan-Ping Wu, Bryan E Figueroa, Martina Metzler, Véronique M André, Elizabeth J Slow, Lynn Raymond, Robert Friedlander, Michael S Levine, Blair R Leavitt, Michael R Hayden.   

Abstract

Huntington disease (HD) is a neurodegenerative disorder caused by an expanded CAG tract in the HD gene. Polyglutamine expansion of huntingtin (htt) results in early, progressive loss of medium spiny striatal neurons, as well as cortical neurons that project to the striatum. Excitotoxicity has been postulated to play a key role in the selective vulnerability of striatal neurons in HD. Early excitotoxic neuropathological changes observed in human HD brain include increased quinolinate (QUIN) concurrent with proliferative changes such as increased spine density and dendritic length. In later stages of the disease, degenerative-type changes are apparent, such as loss of dendritic arborization, a reduction in spine density and reduced levels of 3-hydroxykynurenine and QUIN. It is currently unknown whether sensitivity to excitotoxic stress varies between initiation and progression of disease. Here, we have assessed the excitotoxic phenotype in the YAC128 mouse model of HD by examining the response to excitotoxic stress at different stages of disease. Our results demonstrate that YAC128 mice display enhanced sensitivity to NMDA ex vivo and QUIN in vivo before obvious phenotypic changes. In contrast, 10-month-old symptomatic YAC128 mice are resistant to QUIN-induced neurotoxicity. These findings are paralleled by a significant increase in NMDAR-mediated membrane currents in presymptomatic YAC128 dissociated medium spiny neurons progressing to reduced NMDAR-mediated membrane currents with disease progression. These data highlight the dynamic nature of the mutant htt-mediated excitotoxic phenotype and suggests that therapeutic approaches to HD may need to be altered, depending on the stage and development of the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228972      PMCID: PMC2729178          DOI: 10.1523/JNEUROSCI.5473-08.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  83 in total

1.  Huntington's disease transgenic mice are resistant to global cerebral ischemia.

Authors:  Johannes Schiefer; Anke Alberty; Tatjana Dose; Sabine Oliva; Johannes Noth; Christoph M Kosinski
Journal:  Neurosci Lett       Date:  2002-12-13       Impact factor: 3.046

2.  The HD mutation does not alter neuronal death in the striatum of Hdh(Q92) knock-in mice after mild focal ischemia.

Authors:  Shobu Namura; Lorenz Hirt; Vanessa C Wheeler; Kim M McGinnis; Paige Hilditch-Maguire; Michael A Moskowitz; Marcy E MacDonald; Francesca Persichetti
Journal:  Neurobiol Dis       Date:  2002-10       Impact factor: 5.996

3.  Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model.

Authors:  Bryan R Jarabek; Robert P Yasuda; Barry B Wolfe
Journal:  Brain       Date:  2003-12-08       Impact factor: 13.501

4.  The termination of fibres from the cerebral cortex and thalamus upon dendritic spines in the caudate nucleus: a study with the Golgi method.

Authors:  J M Kemp; T P Powell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1971-09-30       Impact factor: 6.237

5.  Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.

Authors:  Carlos Cepeda; Raymond S Hurst; Christopher R Calvert; Elizabeth Hernández-Echeagaray; Oanh K Nguyen; Emily Jocoy; Lindsey J Christian; Marjorie A Ariano; Michael S Levine
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

6.  Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.

Authors:  Lijun Li; Timothy H Murphy; Michael R Hayden; Lynn A Raymond
Journal:  J Neurophysiol       Date:  2004-07-07       Impact factor: 2.714

7.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.

Authors:  Elizabeth J Slow; Jeremy van Raamsdonk; Daniel Rogers; Sarah H Coleman; Rona K Graham; Yu Deng; Rosemary Oh; Nagat Bissada; Sazzad M Hossain; Yu-Zhou Yang; Xiao-Jiang Li; Elizabeth M Simpson; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2003-07-01       Impact factor: 6.150

8.  Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease.

Authors:  Melinda M Zeron; Herman B Fernandes; Claudia Krebs; Jacqueline Shehadeh; Cheryl L Wellington; Blair R Leavitt; Kenneth G Baimbridge; Michael R Hayden; Lynn A Raymond
Journal:  Mol Cell Neurosci       Date:  2004-03       Impact factor: 4.314

9.  Depletion of wild-type huntingtin in mouse models of neurologic diseases.

Authors:  Yu Zhang; Mingwei Li; Martin Drozda; Minghua Chen; Shengjun Ren; Rene O Mejia Sanchez; Blair R Leavitt; Elena Cattaneo; Robert J Ferrante; Michael R Hayden; Robert M Friedlander
Journal:  J Neurochem       Date:  2003-10       Impact factor: 5.372

10.  Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology.

Authors:  Irina G Stavrovskaya; Malini V Narayanan; Wenhua Zhang; Boris F Krasnikov; Jill Heemskerk; S Stanley Young; John P Blass; Abraham M Brown; M Flint Beal; Robert M Friedlander; Bruce S Kristal
Journal:  J Exp Med       Date:  2004-07-19       Impact factor: 14.307

View more
  55 in total

1.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

2.  Differential electrophysiological changes in striatal output neurons in Huntington's disease.

Authors:  Véronique M André; Carlos Cepeda; Yvette E Fisher; My Huynh; Nora Bardakjian; Sumedha Singh; X William Yang; Michael S Levine
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

3.  Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.

Authors:  Ana Saavedra; Albert Giralt; Laura Rué; Xavier Xifró; Jian Xu; Zaira Ortega; José J Lucas; Paul J Lombroso; Jordi Alberch; Esther Pérez-Navarro
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

4.  Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease.

Authors:  Attila D Kovács; Angelika Saje; Andrew Wong; Serena Ramji; Jonathan D Cooper; David A Pearce
Journal:  Neuropharmacology       Date:  2012-06-06       Impact factor: 5.250

5.  The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus.

Authors:  Edoardo Marcora; Mary B Kennedy
Journal:  Hum Mol Genet       Date:  2010-08-25       Impact factor: 6.150

6.  Temporary inhibition of AMPA receptors induces a prolonged improvement of motor performance in a mouse model of juvenile Batten disease.

Authors:  Attila D Kovács; Angelika Saje; Andrew Wong; Gábor Szénási; Péter Kiricsi; Eva Szabó; Jonathan D Cooper; David A Pearce
Journal:  Neuropharmacology       Date:  2010-10-29       Impact factor: 5.250

7.  Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background.

Authors:  Melissa K Strong; Amber L Southwell; Jennifer M Yonan; Michael R Hayden; Grant R Macgregor; Leslie M Thompson; Oswald Steward
Journal:  J Huntingtons Dis       Date:  2012

8.  Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.

Authors:  Clare M Gladding; Jing Fan; Lily Y J Zhang; Liang Wang; Jian Xu; Edward H Y Li; Paul J Lombroso; Lynn A Raymond
Journal:  J Neurochem       Date:  2014-04-02       Impact factor: 5.372

9.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease.

Authors:  Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero
Journal:  Neurobiol Dis       Date:  2016-09-10       Impact factor: 5.996

10.  Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Authors:  Carlos Cepeda; Laurie Galvan; Sandra M Holley; Shilpa P Rao; Véronique M André; Elian P Botelho; Jane Y Chen; Joseph B Watson; Karl Deisseroth; Michael S Levine
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.